Modality
Radioligand
MOA
SGLT2i
Target
VEGF
Pathway
Sphingolipid
Melanoma
Development Pipeline
Preclinical
~Jul 2016
→ ~Oct 2017
Phase 1
Jan 2018
→ Aug 2027
Phase 1Current
NCT04912901
1,773 pts·Melanoma
2018-01→2027-08·Recruiting
1,773 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-08-071.4y awayInterim· Melanoma
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P1
Recruit…
Catalysts
Interim
2027-08-07 · 1.4y away
Melanoma
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04912901 | Phase 1 | Melanoma | Recruiting | 1773 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Motazanubrutinib | Biogen | Preclinical | CD38 | |
| ALN-5628 | Alnylam | Phase 1/2 | APOC3 |